Head-to-head · free
Teva Pharmaceutical Industries Limited vs 10x Genomics, Inc.
TEVA vs TXG — return on capital, cash generation, margins and balance sheet side by side.
TEVA
5 / 7
measures where TEVA leads
TXG
2 / 7
measures where TXG leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | TEVA · FY2025 | TXG · FY2025 |
|---|---|---|
| Revenue | $1.5B | $642.8M |
| Net income | $1.4B | (43.5M) |
| Revenue growth (yearly, multi-year) | -44.6% | 7.0% |
| Free cash flow | — | $130.1M |
| Free cash flow margin | — | 20.2% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | 21.2% | -5.8% |
| Gross margin | 51.8% | 69.1% |
| Operating margin | 22.9% | -17.2% |
| Net debt / EBITDA | 4.19x | 27.61x |
Figures are as reported by each company; latest fiscal year shown.
Where Teva Pharmaceutical Industries Limited's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where 10x Genomics, Inc.'s cash went (FY2025)
- Capital spending
- $5.9M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free